Arcturus targets Q4 2026 Phase III decision for ARCT-032 as it regains global KOSTAIVE rights (NASDAQ:ARCT)
· seekingalpha.com
Arcturus (ARCT) Q2 2026 earnings call recap: Q3 OTC Phase II data, Q4 CF Phase III decision, and regained KOSTAIVE rights.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...